Undisclosed convertibleCAR-T / Astellas, Roche - LARVOL DELTA

Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology (PRNewswire) - "Astellas Pharma Inc...and Poseida Therapeutics, Inc...today announced that Xyphos Biosciences...and Poseida have entered into a research collaboration and license agreement to develop novel convertibleCAR programs by combining the innovative cell therapy platforms from each of the companies....Under the terms of the agreement, the companies plan to combine Poseida's proprietary allogeneic CAR-T platform with Xyphos' ACCELM technology to create one Poseida-developed CAR-T construct to form the basis of two convertibleCAR product candidates targeting solid tumors....Poseida will receive US $50 million upfront plus potential development and sales milestones and contingency payments of up to US $550 million in total."

Licensing / partnership • Oncology • Solid Tumor